Navigation Links
CEL-SCI Corporation Announces 2008 Financial Results

VIENNA, Va., Jan. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION

(NYSE Alternext US: CVM) reports financial results for the fiscal year ended September 30, 2008.

CEL-SCI reported a net loss for fiscal year 2008 of $(7,703,415) versus a net loss of $(9,629,657) in fiscal year 2007. The loss per share per common share for fiscal year 2008 was $(0.07) compared to a net loss per common share in fiscal year 2007 of $(0.10). Included in the loss in 2008 were non-cash expenditures that added up to approximately $3.3 million, including $1.3 million for employee-stock compensation charges and $1.4 million for various consulting and other related expenses.

The net loss included research and development (R&D) expenses of $4,101,563 in 2008 compared to $2,528,528 in 2007. R&D expenses increased due to higher costs associated with preparing for the Company's upcoming Phase III clinical trial of its cancer drug Multikine.

Geert Kersten, Chief Executive Officer said, "We are pleased by the progress we made in fiscal 2008 in preparing for our pivotal trial of Multikine for head and neck cancer. Expenditures for 2009 are expected to be significantly reduced because of the completion of the manufacturing facility and other material reductions in expenditures. Our focus now is to secure strategic partners to assist us in funding the Phase III study of our cancer drug."

The report by the Company's accountants also contained a "going concern" qualification. This means that based upon only the existing and committed amount of cash in CEL-SCI today, the accountants cannot be sure that CEL-SCI will have enough cash to stay in business until January 2010. As is clearly explained in the Company's 10-K filing, CEL-SCI's management is aware of this, and is currently working on licensing agreements (in addition to the two agreements it currently has with Teva Pharmaceuticals and Orient Europharma), joint ventures and/or financings to start the Phase III clinical trial with its cancer drug Multikine. In addition, in late December 2008 CEL-SCI put in place a $5 million equity line of credit. In the meantime, in light of the challenging capital markets, management has been very successful in reducing its monthly cash expenditures.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.

                                CEL-SCI CORPORATION
                       YEARS ENDED SEPTEMBER 30, 2008 and 2007

                                                   2008              2007

    GRANT REVENUE AND OTHER                      $5,065           $57,043

      Research and development (excluding
        R&D depreciation of $124,705 and
         $91,292 respectively,
         included below)                      4,101,563         2,528,528
      Depreciation and amortization             215,060           176,186
      General & administrative                5,200,735         6,704,538

      Total operating expenses                9,517,358         9,409,252

    NET OPERATING LOSS                       (9,512,293)       (9,352,209)

    GAIN ON DERIVATIVE INSTRUMENTS            1,799,393           868,182

    COSTS ASSOCIATED WITH CONVERTIBLE DEBT            -                 -

    INTEREST INCOME                             483,252           562,973

    INTEREST EXPENSE                           (473,767)       (1,708,603)

    NET LOSS                                $(7,703,415)      $(9,629,657)

    DIVIDENDS                                  (424,815)                -

     SHAREHOLDERS                           $(8,128,230)      $(9,629,657)

          BASIC                                  $(0.07)           $(0.10)
          DILUTED                                $(0.07)           $(0.10)

          BASIC                             117,060,866        97,310,488
          DILUTED                           117,060,866        97,310,488

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
3. CEL-SCI Takes Delivery of New Manufacturing Facility
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
6. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
7. CEL-SCI to Present at the Noble Financial Conference
8. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
9. Mach One Corporation Enters Letter of Intent
10. Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
11. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
Post Your Comments:
(Date:11/24/2015)... Worcester, Mass. (PRWEB) , ... November 24, 2015 ... ... need to maintain healthy metabolism. But unless it is bound to proteins, copper ... Institutes of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a ...
(Date:11/24/2015)... RALEIGH, N.C. , Nov. 24, 2015  Clintrax Global, Inc., ... Raleigh, North Carolina , today announced that the company has ... earnings represented a 391% quarter on quarter growth posted for Q3 ... Kingdom and Mexico , with the ... place in December 2015. --> United Kingdom ...
(Date:11/24/2015)... Muncie, IN (PRWEB) , ... November 24, 2015 , ... ... its newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to ... in the last few years. Many AMA members have embraced this type of racing ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
Breaking Biology Technology:
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):